OxyContin maker Purdue Pharma is considering filing for bankruptcy protection to protect itself from potential liability from more than 1,000 lawsuits, according to a new report.

The Wall Street Journal said Monday the company has hired at least two companies known as restructuring advisers, and added a restructuring specialist as chairman of its board. While the Connecticut-based company has no significant debt, sources told the Journal, filing Chapter 11 bankruptcy would halt the lawsuits against it and open the potential for the claims to be decided by a bankruptcy court.

Purdue is being sued by a number of cities, counties and states over its role in the ongoing opioid epidemic, which it allegedly contributed to through its marketing and sales efforts

In one of those cases, Purdue asked a court Monday to throw out a lawsuit filed by Massachusetts’ attorney general that accuses the company, its owners and top executives of deceiving patients and doctors about the risks of opioids.

In its most expansive response to date, Purdue argued in a motion filed late Friday that the state makes “sensational and inflammatory allegations” in its bid to hold the company accountable for America’s deadly opioid addiction crisis, and called for the lawsuit to be dismissed “as oversimplified scapegoating based on a distorted account of the facts.”

Jillian Fennimore, a spokeswoman for Democratic Attorney General Maura Healey, said Monday the office would fight the attempt to dismiss the case but did not immediately comment on specific arguments made in the company’s filing.

The lawsuit, filed last year and later amended after the company lost a bid to keep portions of it confidential, claims the company sought to profit off a crisis it helped trigger by telling doctors that OxyContin had a low addiction risk and pushing prescribers to keep patients on the drug longer.

Court documents submitted by the state claimed a member of the Sackler family that owns Purdue Pharma said at a launch party for the opioid painkiller in the 1990s that it would be “followed by a blizzard of prescriptions that will bury the competition.”

The company contends the state is presenting internal company documents in a misleading fashion.

“Recognizing the weakness of its legal theories, (Massachusetts) has resorted to the creation of a sensationalist and distorted narrative that ignores facts and mischaracterizes numerous e-mails and business documents,” the motion states.

Healey’s lawsuit is among more than 1,000 by state and local governments that are pending against drug makers in connection with the opioid crisis that claimed more than 72,000 lives in 2017, according to federal statistics. While most of the suits name multiple defendants, the Massachusetts case focuses solely on Purdue and the Sackler family.

Purdue contends in its latest court filing that many of the marketing and labeling issues raised by Massachusetts around OxyContin have already been addressed by the U.S. Food and Drug Administration and in a 2007 consent agreement that stemmed from an earlier criminal case.

The company also points to the state’s own data and policies in a bid to weaken the basis for the lawsuit, including a recent Department of Public Health report indicating that fentanyl and other illegal drugs — and not prescription painkillers — played a direct role in the vast majority of overdose deaths in Massachusetts last year.

Moreover, Purdue noted, state-funded health care programs cover Purdue’s opioid products as “brand preferred” medications.

In a 2017 report to the state Legislature, however, Republican Gov. Charlie Baker’s administration sought to connect the dots between prescription painkillers and the addiction scourge.

“Compared to the general population, those who received three months of prescribed opioids in 2011 were 4 times as likely to die from an opioid-related overdose within one year, and 30 times as likely to die of an opioid-related overdose within five years,” the report stated.